Please assess the completion status of the following clinical trial:

Trial Title: A Study of Tanezumab in Adults With Chronic Low Back Pain

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 5.0

Eligibility Criteria:
Inclusion Criteria:~* Present with duration of low back pain of ≥3 months requiring regular use of analgesic medication (\>4 days per week for the past month). Analgesic medication may consist of NSAIDs, selective COX-2 inhibitors, immediate release opioids, or combinations, with certain protocol-defined limitations.~* Primary location of low back pain must be between the 12th thoracic vertebra and the lower gluteal folds, with or without radiation into the posterior thigh~* Must meet criteria for pain severity and global assessment of low back pain at Screening and Baseline visits~* Female patients of child-bearing potential (and male patients with female partners who are of child-bearing potential) must use 2 methods of contraception throughout the study~* Patients must be willing to discontinue all pain medications for chronic low back pain except rescue medication and not use prohibited pain medications throughout the duration of the study~Exclusion Criteria:~* History of lumbosacral radiculopathy within the past 2 years.~* Back pain due to visceral disorder (eg, endometriosis).~* Back pain due to major trauma or osteoporotic compression fracture in the past 6 months.~* History of rheumatoid arthritis, seronegative spondyloarthropathy, Paget's disease of spine, pelvis or femur; fibromyalgia; tumors or infections of the spinal cord.~* Surgical intervention during the past 6 months for the treatment of low back pain or plans for surgical intervention during the course of the study.~* Current or pending worker's compensation, litigation, disability, or any other monetary settlement regarding his/her CLBP or any other pain condition, or any closed claim within the past 5 years.~* Use of any analgesic or muscle relaxant within 48 hours prior to the five days before Baseline~* Patients receiving only acetaminophen, gabapentin or pregabalin to manage their chronic low back pain.~* Patients taking \>325 mg/day of aspirin.~* Use of any antidepressants with the exception of stable treatment with selective serotonin reuptake inhibitors (SSRIs).~* Use of any sedatives/hypnotics, anxiolytics, tranquilizers, or benzodiazepines unless daily dose has been stable and will remain unchanged throughout the study period.~* Systemic corticosteroid therapy within 30 days (inhaled and topical corticosteroids are permitted).~* Local or epidural injection of corticosteroids, as well as injections of corticosteroids in the back within 3 months.~* Botulinum toxin (Botox®) injection for chronic low back pain within 4 months.~* Requirement for new, concomitant physiotherapy including, but not limited to, transdermal electroneural stimulation (TENS), massage or spinal manipulation for the duration of the study period.~* Active or suspected esophageal, gastric, pyloric channel, or duodenal ulceration within 3 months, or any history of gastrointestinal bleeding.~* Current use of lithium or anticoagulant agents.~* Known hypersensitivity or intolerance to NSAIDs; history of asthma, urticaria, or allergic type reactions after taking aspirin or NSAIDs.~* Inflammatory bowel disease, a chronic or acute renal or hepatic disorder, a significant coagulation defect, or other condition that might preclude the use of an NSAID.~* History of intolerance to acetaminophen or paracetamol or any of its excipients.~* History of known alcohol, analgesic or narcotic abuse within 2 years.~* Presence of drugs of abuse (including prescription medications without a valid prescription), other illegal drugs or marijuana in the urine toxicology screen obtained at Screening.~* History of allergic or anaphylactic reaction to a therapeutic or diagnostic monoclonal antibody or IgG fusion protein.~* Use of biologics other than study medication, including any live vaccines, within 3 months, or use during the study (intranasal Flumist® vaccine is an exception).~* Signs and symptoms of clinically significant cardiac disease.~* Diagnosis of a transient ischemic attack within the 6 months, or residual deficits from stroke that would preclude completion of required study activities.~* History of cancer within 5 years.~* Use of any investigational medication within 30 days (3 months for investigational biologics).~* Expected to undergo a therapeutic procedure or to use any analgesic other than those specified in the protocol throughout the study period.~* Previous exposure to exogenous NGF or to an anti NGF antibody.~* Screening laboratory results and blood pressure within specified limits.~* Positive Hepatitis B, Hepatitis C, or human immunodeficiency virus (HIV) tests at screening.~* History, diagnosis, or signs and symptoms of clinically significant neurological disease.~* History, diagnosis, signs or symptoms of any clinically significant psychiatric disorder.~* Hospital admission for depression or suicide attempt within 5 years or active, severe major depression at Screening.~* Likelihood of being non compliant with study procedures.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Tanezumab 20 mg IV (Type: EXPERIMENTAL): None
- Tanezumab 10 mg IV (Type: EXPERIMENTAL): None
- Tanezumab 5 mg IV (Type: EXPERIMENTAL): None
- Naproxen (Type: ACTIVE_COMPARATOR): None
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).